Expert Opinion on Pharmacotherapy最新文献_第10页

The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia. 5- α还原酶抑制剂联合治疗前列腺增生的最新临床试验结果。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.1080/14656566.2025.2453586

Konstantinos Kapriniotis, Ioannis Manolitsis, Patrick Juliebo-Jones, Amelia Pietropaolo, Arman Tsaturyan, Senol Tonyali, Emre Sener, Esteban Emiliani, Ali Talyshinskii, Theodoros Karagiotis, Bhaskar Somani, Lazaros Tzelves

{"title":"The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia.","authors":"Konstantinos Kapriniotis, Ioannis Manolitsis, Patrick Juliebo-Jones, Amelia Pietropaolo, Arman Tsaturyan, Senol Tonyali, Emre Sener, Esteban Emiliani, Ali Talyshinskii, Theodoros Karagiotis, Bhaskar Somani, Lazaros Tzelves","doi":"10.1080/14656566.2025.2453586","DOIUrl":"10.1080/14656566.2025.2453586","url":null,"abstract":"Introduction: BPH/male LUTS is a prevalent condition in the aging male population with multifactorial pathophysiology. Pharmacotherapy remains the cornerstone of treatment in patients who fail conservative treatment. 5-α-Reductase inhibitors (5-ARIs) are the only class of medication shown to reduce the risk of acute retention and BPH-related surgery and, thus, are commonly used along with other \"short acting\" medications in combination treatments.Areas covered: Combination treatments with α-blockers and 5-ARIs have been investigated extensively in high quality trials that prove the long-term efficacy of such treatments with acceptable rates of side effects. Combination treatments involving 5-ARIs and other classes of medications (anticholinergics, b3 agonists, PDEI) have been shown to be beneficial in the short term and but studies with longer follow-up periods are required to fully establish their role.Expert opinion: A-blocker/5-ARI combination treatment is a reasonable approach for patients with male LUTS/BPH who are at increased risk of disease progression or have incomplete response to monotherapies. Other combination treatments with 5-ARIs and PDEI or anticholinergics/β-3 agonists can be tried based on predominant symptoms or side effect profile, but patients should be informed about the lack of long-term data.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"301-311"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of current and emerging estrogen receptor agonists for vaginal atrophy. 目前和新出现的雌激素受体激动剂治疗阴道萎缩的综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-08 DOI: 10.1080/14656566.2025.2451150

Gilbert G G Donders, Karolina Akinosoglou, Zoë Massie, And Sabriye Özçelik

{"title":"Review of current and emerging estrogen receptor agonists for vaginal atrophy.","authors":"Gilbert G G Donders, Karolina Akinosoglou, Zoë Massie, And Sabriye Özçelik","doi":"10.1080/14656566.2025.2451150","DOIUrl":"10.1080/14656566.2025.2451150","url":null,"abstract":"Introduction: Vulvovaginal atrophy (VVA) predominantly affects postmenopausal women due to hormonal decline but can also occur in premenopausal women with conditions such as primary ovarian insufficiency or exposure to anti-estrogen medications. Contributing factors include smoking and certain medical treatments. Symptoms like dyspareunia and loss of sexual function affect many women but are underreported due to stigma and lack of awareness. Current treatments range from over-the-counter lubricants to hormonal therapies like estrogen receptor agonists, which improve vaginal elasticity and moisture with minimal systemic absorption.Areas covered: This review evaluates current and emerging estrogen receptor agonists for VVA treatment. A comprehensive search was conducted using PubMed between August and September 2024, supplemented by snowball sampling from key references.Expert opinion: Despite its prevalence, VVA remains underdiagnosed, with increasing recognition due to longer lifespans and focus on quality of life. Diagnosis involves comprehensive symptom assessment, including sexual history, urinary tract infection frequency, and clinical exams, with vaginal pH measurements and smear microscopy to determine the condition's severity. Treatment usually involves estrogen, but not all women can safely use it, and preferences toward estrogen must be respected. Alternatives like selective estrogen receptor modulators (SERMs) such as prasterone and ospemifene show promise but need more long-term safety data. Emerging options like E3 and E4 demonstrate efficacy and safety in low doses. Future treatments will emphasize convenience and adherence, making timely diagnosis and management of VVA routine in women's health care.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"249-255"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New pharmacotherapeutic strategies for drug-resistant Candida infections: a review. 耐药性念珠菌感染的新药物治疗策略：综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-02 DOI: 10.1080/14656566.2024.2433605

Jesse Raposa, Jose A Vazquez

{"title":"New pharmacotherapeutic strategies for drug-resistant Candida infections: a review.","authors":"Jesse Raposa, Jose A Vazquez","doi":"10.1080/14656566.2024.2433605","DOIUrl":"10.1080/14656566.2024.2433605","url":null,"abstract":"Introduction: Candida species produce a wide array of infections ranging from mucocutaneous to systemic infections. Candida albicans remains the most common species identified; however, the non-albicans Candida species have continued to increase as the diagnosis and therapeutic regimens have progressed.Areas covered: This review with discussion of the various Candida species, especially the non-albicans species, some of the important mechanisms of resistance, and newer in vitro and clinical studies describing the recent and novel antifungal options such as rezafungin, ibrexafungerp, and oteseconazole, along with a novel antifungal, fosmanogepix.Expert opinion: Initial antifungal therapy is frequently obsolete due to the expansion of antifungal resistance. This is especially true with C. glabrata, C. krusei, and most recently with C. auris. The newer and novel antifungals discussed here will add valuable tools to our antifungal armamentarium to be able to appropriately and adequately treat and manage these difficult infections. Each of the antifungals has unique and novel properties that will expand the arsenal useful to treat these fungal infections in the years to come.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.5,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments. 应对covid -19后肺纤维化风险：前沿疗法

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-06 DOI: 10.1080/14656566.2024.2438322

Sy Duong-Quy, Cong Nguyen Hai, Tuan Huynh-Anh, Vinh Nguyen-Nhu

{"title":"Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments.","authors":"Sy Duong-Quy, Cong Nguyen Hai, Tuan Huynh-Anh, Vinh Nguyen-Nhu","doi":"10.1080/14656566.2024.2438322","DOIUrl":"10.1080/14656566.2024.2438322","url":null,"abstract":"Introduction: Pulmonary fibrosis (PF) post-COVID-19 has been identified as an important complication of Long-COVID, especially in patients with severe respiratory symptoms. High-resolution computed tomography (HRCT) is the main tool for detecting fibrotic lesions in patients with PF post-COVID-19.Areas covered: We conducted a systematic review with the following objectives: (1) to summarize the incidence and disease burden of post‑COVID‑19 pulmonary fibrosis, (2) to provide information on available therapies and drugs for its management, (3) to comprehensively evaluate the initial treatment efficacy of these drugs, and (4) to identify the limitations and challenges associated with current treatment approaches.Expert opinion: Cutting-edge treatments for PF post-COVID-19 are focused on the complex and multifactorial nature of the disease progreession during Long COVID, which involves chronic inflammation, fibroblast activation, and excessive extracellular matrix deposition leading to stiffening and fibrosis of lung tissue. While traditional antifibrotic drugs with nintedanid and pirfenidone are being used, novel therapies with anti-interleukines, mesenchymal stem cells, and Rho-kinase inhibitors promise the new treatment approaches for patients with PF post-COVID-19. Further research and clinical trials are needed to determine the most effective strategies for managing this complex condition, with the goal of improving patient outcomes and quality of life.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"75-84"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease. 慢性肾脏疾病高磷血症当前和新兴治疗模式的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1080/14656566.2024.2441328

Davide Salera, Antonio Bellasi, Lucia Del Vecchio, Francesco Locatelli

{"title":"Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease.","authors":"Davide Salera, Antonio Bellasi, Lucia Del Vecchio, Francesco Locatelli","doi":"10.1080/14656566.2024.2441328","DOIUrl":"10.1080/14656566.2024.2441328","url":null,"abstract":"Introduction: Hyperphosphatemia in advanced CKD often accompanies high PTH and FGF23 levels, impaired bone mineralization, ectopic calcifications, and increased cardiovascular risks. Novel treatments are now available to lower serum phosphorus effectively. However, safety, tolerability, and patient adherence must be evaluated to determine the best therapeutic option for hyperphosphatemia.Areas covered: This review examines available treatment strategies for hyperphosphatemia in CKD patients and new emerging treatments, emphasizing the latest inhibitors of active phosphate absorption.Expert opinion: Despite the numerous compounds available, managing hyperphosphatemia in CKD remains challenging. While many phosphate binders exist, they often have limitations and side effects. Aluminum carries significant toxicity risks. Calcium-based binders are effective but can cause hypercalcemia and vascular calcification. Lanthanum is absorbed in the gut, but its long-term tissue deposition appears clinically irrelevant. Sevelamer reduces vascular calcification but has inconclusive data and gastrointestinal side effects. Iron-based binders are effective but may cause gastrointestinal discomfort and lack long-term outcome data. New inhibitors of intestinal phosphate absorption show promise with low pill burden but need more clinical validation. Although these newer compounds might eventually improve phosphate management in CKD patients, enhancing adherence and reducing pill burden, future studies are required to elucidate the best treatment for hyperphosphatemia.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"85-100"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer. 治疗结直肠癌腹膜转移的药物疗法进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-03 DOI: 10.1080/14656566.2024.2435946

Janson Kappen, Omar Abdel-Rahman

引用次数: 0

Letter to the editor - 'Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia'. 致编辑的信--"olezarsen，一种治疗高甘油三酯血症的肝脏导向 APOC3 ASO疗法"。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1080/14656566.2024.2432487

Melvin Khee Shing Leow

引用次数: 0

An update on the pharmacotherapy of gout. 痛风药物治疗的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.1080/14656566.2024.2442028

Jack Shi Jie Yuan, Anush Shashidhara, Aman Sutaria, Syed Haider Tahir, Hasan Tahir

{"title":"An update on the pharmacotherapy of gout.","authors":"Jack Shi Jie Yuan, Anush Shashidhara, Aman Sutaria, Syed Haider Tahir, Hasan Tahir","doi":"10.1080/14656566.2024.2442028","DOIUrl":"10.1080/14656566.2024.2442028","url":null,"abstract":"Introduction: Gout is a common form of acute inflammatory arthritis caused by the deposition of monosodium urate crystals within synovium of joints. This leads to severe pain, reducing quality of life for patients with this condition.Areas covered: This review summarizes the treatment of both acute flares of gout and urate-lowering therapy based on guidance from various major international societies. We have also covered new emerging therapies that have not yet reached clinical practice.Expert opinion: Standard pharmacotherapies for gout flares include the options of colchicine, NSAIDs and oral or intramuscular corticosteroids, with IL-1 inhibitors newly established as an option for flare refractory to standard therapies. Urate-lowering therapies aim to prevent gout flares, with an emphasis on treat-to-target strategy; the escalation of therapies until the target serum uric acid is reached. Initial treatments include allopurinol and febuxostat, with uricosuric agents, probenecid, sulfinpyrazone and benzbromarone, as adjuncts. There are also emerging therapies in development. However, there is increasing personalization of treatment, adjusting pharmacotherapy depending on comorbidities, such as chronic kidney disease and ischemic heart disease, as well as patient preference.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"101-109"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review. GLP-1受体激动剂在肥胖相关阻塞性睡眠呼吸暂停治疗中的应用现状：综述

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-06 DOI: 10.1080/14656566.2024.2437525

Ali A El-Solh, Erin Gould, Keziah Aibangbee, Tanya Jimerson, Rebecca Hartling

{"title":"Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.","authors":"Ali A El-Solh, Erin Gould, Keziah Aibangbee, Tanya Jimerson, Rebecca Hartling","doi":"10.1080/14656566.2024.2437525","DOIUrl":"10.1080/14656566.2024.2437525","url":null,"abstract":"Introduction: Traditionally, obstructive sleep apnea (OSA) management has focused on continuous positive airway pressure therapy, oral appliances, and in some cases, surgical interventions. However, these treatments do not directly address the underlying metabolic issues contributing to OSA. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes management, have demonstrated substantial efficacy in promoting weight.Areas covered: This review aims to summarize the potential impact of liraglutide, semaglutide, and tirzepatide in managing obese patients with OSA.Expert opinion: The introduction of GLP-1 RAs has gained attention not only for their ability to produce significant and sustained weight loss but also for their potential to improve OSA symptoms by reducing fat deposition around the upper airway and decreasing systemic inflammation. Emerging clinical trials suggest that GLP-1 RAs may enhance traditional OSA treatments, offering an integrated approach targeting the root cause of obesity in OSA. Additionally, GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease, which are commonly associated with OSA. The future integration of GLP-1 RAs into OSA treatment protocols could mark a paradigm shift toward more comprehensive management strategies, ultimately improving patient outcomes in this complex patient population.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"51-62"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tirzepatide for overweight and obesity management. 替西帕肽用于超重和肥胖管理。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1080/14656566.2024.2436595

Malak Hamza, Dimitris Papamargaritis, Melanie J Davies

{"title":"Tirzepatide for overweight and obesity management.","authors":"Malak Hamza, Dimitris Papamargaritis, Melanie J Davies","doi":"10.1080/14656566.2024.2436595","DOIUrl":"10.1080/14656566.2024.2436595","url":null,"abstract":"Introduction: Tirzepatide is a once-weekly dual agonist, acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is approved at the same doses (5, 10 and 15 mg) for both type 2 diabetes (T2D) and chronic weight management.Areas covered: Following a search in PubMed, clinicaltrials.gov, conference abstracts and Lilly website, we review herein the global phase 3 SURMOUNT program on tirzepatide's safety and efficacy for chronic weight management. Additionally, we discuss findings from the regional SURMOUNT-CN and SURMOUNT-J trials (in East-Asian populations) and the phase 2 SYNERGY-NASH, phase 3 SURMOUNT-OSA and SUMMIT studies on tirzepatide's impact on obesity-related complications. We also explore the clinical implications of SURMOUNT program results, considerations for tirzepatide prescribing for overweight/obesity, ongoing research and evidence gaps.Expert opinion: Tirzepatide marks a new era in overweight/obesity treatment, enabling many to achieve ≥ 20% weight loss. It is well-tolerated with a safety profile similar to GLP-1 receptor agonists. Tirzepatide also results in clinically important improvements in multiple obesity-related complications including sleep apnea, metabolic-dysfunction associated steatohepatitis, heart failure with preserved ejection fraction and diabetes prevention. Ongoing trials will provide further data on tirzepatide's long-term safety, efficacy (including cardiovascular outcomes) and potential cost-effectiveness for managing overweight/obesity and/or T2D.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"31-49"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0